• Madrigal Pharmaceuticals reported new Journal of Hepatology data from a secondary analysis of its Phase 3 MAESTRO-NASH trial.
• Results were presented as a publication, not flagged for a future conference release.
• Rezdiffra showed broadly consistent benefits on liver disease measures across common genetic risk variants tied to MASH progression.
• Findings support use across genetically diverse patients, reducing the need to segment treatment by genotype in near-term commercialization.
• Analysis covered 738 trial participants with genetic testing and paired biopsies, limiting conclusions on rarer variants or small subgroup effects.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060800PRIMZONEFULLFEED9840426) on October 06, 2026, and is solely responsible for the information contained therein.